A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.

You may be eligible if

• Patients with breast cancer (ICD-10: C50)
• A diagnosis of HR+/HER2- locally advanced or metastatic breast cancer
• Endocrine sensitive, endocrine resistant, or de novo mBC patient
• Inclusion date: Date of relapse/stage IV disease/progression leading to initiation of palbociclib+AI